摘要
目的探讨帕利哌酮缓释片治疗精神分裂症的疗效和安全性。方法 60例急性住院精神分裂症患者,口服帕利哌酮缓释片1/日给药,可根据患者病情调整剂量,为期8周。采用阳性和阴性症状量表(PANSS)评价精神症状,个人和社会功能量表(PSP)评价社会功能情况,临床疗效总评量表(CGI-s)评定总体病情,不良反应症状量表(TESS)评估不良反应,分别于治疗前及治疗第1、2、4、8周末进行评估。实验设计为单臂,以自身为对照。结果经口服帕利哌酮缓释片治疗后,研究对象的PANSS总分较治疗前明显下降,差异有统计学意义(t=701.545,P=0.000),PSP分值较治疗前明显提高,差异有统计学意义(t=42.608,P=0.000),CGI-s分值较治疗前明显下降,差异有统计学意义(t=17.869,P=0.000)。未出现严重不良反应,30%病人出现EPS,大多为轻度。结论帕利哌酮缓释片可有效地改善精神分裂症的症状,提高个人和社会功能并具有良好的耐受性。
Objective To evaluate the efficacy and safety of paliperidone extended-release tablets in treatment of schizophrenia. Methods A total of 60 acute hospitalized patients with schizophrenia were enrolled and received paliperidone extended-release tablets once daily for 8 weeks,dose was adjusted according to the severity of condition. The psychiatric symptoms were assessed with the positive and negative symptoms scale（PANSS）, social function was assessed with Personal and Social Performance（PSP）, Clinical Global Impression Scale （CGI-s）evaluate general disease,side effects were done with the Treatment Emergent Symptom Scale （TESS）. All of the scales were evaluated at the baseline and at the ends of week 1,2,4 and 8 treatment. Results After treatment, the PANSS total score decreased significantly （t= 701. 545 ,P~ 0. 000）, the .PSP score was significantly increased （t= 42. 608,P=0. 000）,CGI--s score decreased significantly（t= 17. 869,P=0. 000）,No serious side effects were found. 30% patients had extrapyramidal side effects during the treatment,mostly modest. Conclusion Paliperidone extended-release tablets is effective to improve positive symptoms,negative symptoms and social functions of patients with schizophrenia ,patients have good tolerances to the drug. Paliperidone extended-release tablets provides a valuable new treatment option for schizophrenia.
出处
《中国健康心理学杂志》
2013年第4期511-512,共2页
China Journal of Health Psychology
